Front Line Genomics invites you to their event
About this event
Liquid biopsies remain a promising area of cancer research with the potential to transform how clinicians diagnose, monitor and make treatment decisions. However, obstacles such as low sensitivity and the lack of standardised protocols have hindered their widespread adoption as standard of care testing. Fortunately, ongoing research is carving out a bright future for liquid biopsies in clinical care.
In this 3-part webinar series, you will be guided through the journey of optimising liquid biopsies from the research phase to clinical application. By registering for this series, you will:
Tuesday 29th October at 3pm GMT/ 4pm CET/ 11am EDT
Recent advances in omics technologies have expanded the range of circulating biomarkers at our disposal for the clinical management of cancer patients. The ability to isolate and stabilise multiple analytes from a single blood draw opens the exciting possibility for the use of novel biomarkers in clinical settings.
In this webinar, we will delve into the biology of circulating biomarkers, including cfDNA, RNA and modulating biology with priming agents. We will discuss their clinical significance, the challenges associated with their isolation and analysis, and the potential solutions to enhance their future utility as clinical biomarkers.
Talk 1: Modulating cfDNA biology: Inhibiting cfDNA clearance via priming agents to improve liquid biopsies
Shervin Tabrizi, Attending Physician, Massachusetts General Hospital
Talk 2: Using cfDNA Derived From Pleural Effusion to Diagnose Cancers Affecting The Lung
Antonia Pritchard, Reader, University of the Highlands and Islands
Talk 3: Advancing RNA Liquid Biopsy Technology
Daniel Kim, Assistant Professor, UC Santa Cruz
Tuesday 5th November at 3pm GMT/ 4pm CET/10am EST
A major challenge in the liquid biopsy adoption is the need to reliably detect and analyse multiple analytes and minimise false results. This webinar will focus on standardising workflows, from sample collection and stabilisation to results to minimise these errors, along with the analysis and bioinformatics tools that are improving sensitivity for the detection and interpretation of ultra-rare variants in liquid biopsies.
Talk 1: Optimising Liquid Biopsies for Therapy-Relevant ESR1 Mutations in Breast Cancer
Franziska Fahlteich, Research Assistant, University Hospital Carl Gustav Carus
Talk 2: Pre-Analytical Pitfalls and the Power of Standards: Why ISO for Liquid Biopsies Matters
Amin El-Heliebi, Principal Investigator, Medical University of Graz
Talk 3: Harnessing The Power of dPCR For Multiplex Analysis of Copy Number Variant in Liquid Biopsies in Solid Tumours
Stefania Crucitta, Junior Researcher, University of Pisa
Tuesday 12th November at 3pm GMT /4pm CET/ 10am EST
This webinar will explore the implementation of liquid biopsies in clinical care, highlighting where they are making the most significant impact and strategies for overcoming barriers to their routine use including assessing health economics.
We will cover the application of liquid biopsies in identifying cancer variants, monitoring disease progression and assessing treatment response. We will also discuss the tools and infrastructure needed for liquid biopsy analysis, and the potential cost-savings and patient benefit of widespread liquid biopsy adoption.
Talk 1: Liquid Biopsy-Based Tests For Early Detection And Monitoring of Cancer – Experience With Clinical Studies
Hege Marie Vedeld, Post-doc, Oslo University Hospital
Talk 2: Lessons Learned From The National Lung Cancer ctDNA Pilot
Alastair Greystoke, Professor of Precision Oncology and Honorary Consultant in Medical Oncology, Newcastle University
Talk 3: The Benefits of Circulating miRNAs in Liquid Biopsies
Matthew Murray, Honorary Consultant Paediatric Oncologist, Cambridge University Hospitals NHS Foundation Trust
Hosted by
Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events and webinars. We also produce reports and operate a content-rich website.
